---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004528"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:55:03.575393+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xilio reports FY2023 net loss of $76.4M, Gilead licenses XTX301 for up to $604M

## Summary
- Cash and cash equivalents were $44.7M at Dec 31, 2023, down from $120.4M a year earlier.
- Net loss was $17.7M for Q4 2023 and $76.4M for FY2023, vs $22.5M and $88.2M in 2022.
- Gilead pays $43.5M upfront ($30M cash + $13.5M equity) for exclusive license to XTX301; Xilio eligible for up to $604M in milestones and tiered royalties.
- Plans to initiate Phase 2 trial of XTX101 + atezolizumab in MSS CRC in Q3 2024, with initial data in Q4 2024.
- Cash runway extended into Q2 2025 after Gilead upfront, $11.3M private placement, and workforce reduction of ~21%.

## SEC filing metadata
- accession: 0001558370-24-004528
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024004528/0001558370-24-004528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024004528/xlo-20240401x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004528
- JSON: https://secwatch.observer/filing/0001558370-24-004528.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004528.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837024004528/0001558370-24-004528-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.